Merve Dizdar

Merve Dizdar

Auto-generated profile, based on publicly available information

Merve Dizdar

Department of Obstetrics and Gynecology, Ümraniye Training and Research Hospital

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2023 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Open access
İKİbrahim Kale
İbrahim Kale
MDMerve Dizdar
Merve Dizdar
We aimed to investigate the cardiotrophin-1 (CT-1) concentrations in the serum of pregnant women with preeclampsia. This cross-sectional study was conducted with 88 pregnant women who applied to the Umraniye Training and Research Hospital Gynecology and Obstetrics Clinic between May 2022 and September 2022. The preeclampsia group consisted of 44 pregnant women diagnosed with preeclampsia, and the control group consisted of 44 healthy pregnant women matched with the preeclampsia group in terms of age and body mass index. Demographic characteristics, ultrasound and laboratory findings, perinatal outcomes, and maternal serum CT-1 concentrations were recorded. Both groups were similar in terms of demographic features and the gestational week at blood sampling for CT-1. Preeclampsia and control groups were compared in terms of maternal serum CT-1 concentrations and no significant difference was found between the two groups (2061.4 pg/ml, 2168.5 pg/ml, respectively, p = .516). The preeclampsia group was divided into subgroups as mild and severe preeclampsia according to the severity of the disease and early-onset and late-onset preeclampsia according to the time of onset and compared with the control group in terms of maternal serum CT-1 concentration, no significant difference was found between the groups (p > .005, for all). The serum CT-1 concentration of women whose pregnancy was complicated with preeclampsia was found to be similar to that of healthy controls. Although it has been shown in the literature that high serum CT-1 concentrations are associated with hypertensive heart diseases, its role in the pathophysiology of preeclampsia remains unclear.

9 October 2023 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
IEİlGi Esen
İlGi Esen
İKİbrahim Kale
İbrahim Kale
EDEbru Alıcı Davutoğlu
Ebru Alıcı Davutoğlu
MDMerve Dizdar
Merve Dizdar
RBRahime Nida Bayık
Rahime Nida Bayık
Background: Cervical length measurement is still the most widely used method to predict preterm labor. Recent studies have reported that in addition to cervical length, uterocervical angle (UCA) may also be useful in predicting preterm labor. The main purpose of this study was to evaluate the use of the anterior UCA to predict preterm labor in symptomatic pregnant women with a cervical length of 20 to 30 mm. Methods: In this prospective cohort study, 48 patients with a cervical length of 20 to 30 mm who applied to the emergency department with any preterm labor symptoms, between September 2019 and February 2020, were included as the study group. Cervical length and anterior UCA were measured at the first admission. Of these 48 patients, 12 patients who gave birth before 37 weeks were called the ‘preterm labor group’, and 36 patients who gave birth at 37 weeks or later were named the ‘preterm threatened but delivered at term’ group. The control group consisted of 46 healthy pregnant women who were matched with the study group in terms of age, body mass index (BMI), and the gestational week at which anterior UCA was measured. The three groups were compared in terms of anterior UCA values. Results: The cervical lengths of the ‘preterm labor’ and ‘preterm threatened but delivery at term’ groups were similar and shorter than the control group (25.4 mm, 25.1 mm, and 35 mm, respectively, p < 0.001). Anterior UCA value in the ‘preterm labor’ group (116.1) was found to be significantly higher than both ‘preterm threatened but delivered at the term’ group (100.2) and the control group (98.6) (p = 0.001). Receiver operating curve (ROC) analysis was performed to determine a threshold value of anterior UCA that could predict preterm labor in symptomatic pregnant women with a cervical length of 20 to 30 mm. Area under curve (AUC) analysis of anterior UCA for estimation of preterm labor was 0.647 (p = 0.014, 95% confidence interval (CI) = 0.52–0.77). According to this analysis, the threshold value of anterior UCA was determined as 95.3, with 72% sensitivity, and 63% specificity. Conclusion: The anterior UCA can be used to better predict preterm labor in symptomatic pregnant women with a cervical length of 20 to 30 mm without cervical effacement and dilation.

10 November 2025
Verified
Book Chapter
Open access
PDF file
MDMerve Dizdar
Merve Dizdar
Uterin arter embolizasyonu (UAE), anormal uterin kanaması olan hastalarda cerrahiye alternatif etkili bir tedavi yöntemidir. Takayasu arteriti gibi otoimmün hastalıklar, embolizasyon sonrası komplikasyon riskini artırabilir. Bu olgu sunumunda, leiomyom nedeniyle dirençli anormal uterin kanaması olan ve cerrahi kontrendikasyonu bulunan Takayasu arteritli bir hastada başarılı UAE uygulanması anlatılmaktadır. Preoperatif görüntüleme, dikkatli multidisipliner yaklaşım ve uygun perioperatif yönetim ile komplikasyonlar önlenmiş, hastada semptomatik iyileşme sağlanmıştır.

10 November 2025
Verified
Book
Open access
PDF file
ADArzu Bostancı Durmuş
Arzu Bostancı Durmuş
BBBURAK BARUTCU
BURAK BARUTCU
BABetül Akgün Aktaş
Betül Akgün Aktaş
GTGizem Toker
Gizem Toker
HTHatice Laçin Tuğan
Hatice Laçin Tuğan
DBDeniz Çokay Bektaş
Deniz Çokay Bektaş

3 July 2023 in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
Verified
Journal Article
Closed access
MDMerve Di̇zdar
Merve Di̇zdar
İKİbrahim Kale
İbrahim Kale
IEİlgi Esen
İlgi Esen
RBRahime Bayik
Rahime Bayik
Aim: To evaluate the variability of anti-Mullerian hormone (AMH) and antral follicle count (AFC) in an unstimulated menstrual cycle. Materials and Method: The study was designed on 50 women who had regular menstrual cycles and did not have any systemic disease or previous ovarian surgery. Serum AMH levels and antral follicle counts of all participants were evaluated three times in the same menstrual cycle in the early and late follicular phase and luteal phase. To evaluate the intracyclic AMH fluctuation according to age, participants were divided into two groups; younger (<35 years) and older (35 years old). Results: The mean age of the participants was 30.8, the mean BMI was 23.4 kg/m2, and the mean menstrual cycle duration was 28.5 days. Mean AMH values evaluated at three different times in the menstrual cycle, early follicular, late follicular, and luteal phase, were 2.66 ng/dl and mean AFC 17.4. The highest mean AMH level and AFC were detected in the late follicular phase and this was statistically significant for AMH level but not for AFC (p= 0.044, p=0.307, respectively). The intracyclic fluctuation of AMH was greater in the younger patient group. The coefficient of variation was 0.241 in the younger patient group, and 0.132 in the older patient group. (p=0.011) Conclusion: Serum AMH levels fluctuate throughout the menstrual cycle and the highest serum AMH level was detected in the late follicular phase. AFC remained stable throughout the cycle. Amaç: Çalışmada düzenli menstruel siklusu olan sağlıklı hastalarda, doğal siklusta serum anti-Mullerian hormon değerlerinin ve antral follikül sayımının, intra-menstruel değişiminin saptanması amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya menstruel siklusu düzenli olan, sistemik hastalık ve geçirilmiş over cerrahi öyküsü olmayan, son iki ay içinde hormonal kontraseptif preparat kullanmamış olan 50 sağlıklı kadın dahil edilmiştir. Serum anti-Mullerian hormon seviyeleri ve antral follikül sayısı stimüle edilmemiş aynı siklus içerisinde erken folliküler faz, geç folliküler faz ve luteal fazda olmak üzere üç kez değerlendirilmiştir. Yaş gruplarına göre serum anti-Mullerian hormon seviyelerinin karşılaştırılması amacıyla da hastalar genç (<35 yaş) ve ileri yaş (35 yaş) olmak üzere iki gruba ayrılmıştır. Bulgular: Hastaların yaş ortalaması 30.8, vücut kitle indeksi ortalaması 23.4 kg/m2 ve ortalama siklus uzunluğu 28.5 gün olarak bulunmuştur. Aynı menstruel siklusta erken folliküler faz, geç folliküler faz ve luteal faz olmak üzere üç kez değerlendirilen serum anti-Mullerian hormon seviyesi ortalaması 2.66 ng/dl ve ortalama antral follikül sayısı 17.4 olarak saptanmıştır. En yüksek serum anti-Mullerian hormon seviyesi ve antral follikül sayısı geç folliküler fazda bulunmuştur ve bu fark antral follikül sayısında olmasa da serum anti-Mullerian hormon seviyesi karşılaştırmasında istatistiksel olarak anlamlı bulunmuştur. (p=0.307, p= 0.044). Serum anti-Mullerian hormon variabilitesi genç grupta, ileri yaş gruba kıyasla daha fazla olarak saptanmış olup istatistiksel olarak anlamlı bulunmuştur. (0.241 vs 0.132, p=0.011) Sonuç: Serum anti-Mullerian hormon seviyeleri menstruel siklus içinde dalgalanmalar göstermekte olup, en yüksek serum anti-Mullerian hormon seviyesi geç folliküler fazda saptanmıştır. Antral follikül sayımı menstruel siklus boyunca sabit kalmıştır.

21 August 2026 in Gynecology Obstetrics & Reproductive Medicine
Verified
Journal Article
Open access
PDF file
MDMerve Dizdar
Merve Dizdar
FBFazilet Kubra Boynukalin
Fazilet Kubra Boynukalin
BDBetul Dundar
Betul Dundar
MGMeral Gultomruk
Meral Gultomruk
IKIbrahim Kale
Ibrahim Kale
GBGurkan Bozdag
Gurkan Bozdag
OBJECTIVE: To compare embryo ploidy rates and ovarian response outcomes between gonadotropin-releasing hormone (GnRH) antagonist and progestin-primed ovarian stimulation (PPOS) cycles with recombinant luteinizing hormone (rLH) administered from stimulation onset. STUDY DESIGN: This retrospective within-patient cohort study included 41 women undergoing in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) at a single center. Each patient completed both GnRH antagonist and PPOS cycles with rLH supplementation initiated on stimulation day 1. Cycles using GnRH agonists, urinary LH, random-start approaches, or with major gonadotropin dose discrepancies were excluded. The primary outcome was euploidy rate per biopsied blastocyst. Secondary outcomes included gonadotropin consumption, numbers of retrieved and mature oocytes, fertilization, blastulation, and euploidy per metaphase II (MII) oocyte. Paired t-tests or Wilcoxon signed-rank tests were used as appropriate. Statistical significance was set at p <0.05. RESULTS: In total, 175 blastocysts were biopsied (86 antagonists; 89 PPOS). Euploidy rates per biopsied embryo were comparable (32.36% vs 33.72%). No significant differences were observed in oocyte yield, MII oocytes, fertilization, or blastulation rates. Gonadotropin consumption was significantly higher in antagonist cycles (p = 0.013), while hormonal profiles at trigger were comparable. CONCLUSION: When rLH supplementation is standardized, PPOS and antagonist protocols yield comparable embryo ploidy and similar ovarian response in IVF-PGT-A cycles. PPOS remains an effective alternative, particularly in freeze-all strategies. Larger prospective studies are needed to clarify the benefit of rLH across stimulation protocols.